Glucose Lowering Effect of SGLT2 Inhibitors: A Review of Clinical Studies.

Kim,  Hae Jin

doi:2014.15.3.146

J Korean Diabetes > Volume 15(3); 2014 > Article

Focused Issue

The Journal of Korean Diabetes 2014;15(3):146-150.
DOI: https://doi.org/10.4093/jkd.2014.15.3.146 Published online September 30, 2014.

SGLT2 억제제의 혈당 강하 효과

김혜진

Glucose Lowering Effect of SGLT2 Inhibitors: A Review of Clinical Studies.

Hae Jin Kim

Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. jinkim@ajou.ac.kr

Abstract

There are numerous glucose lowering agents in clinical use for type 2 diabetic patients, yet most do not achieve glycemic targets. Recently, inhibitors of the sodium glucose cotransporter 2 (SGLT2) have been developed, which show great potential of being a novel therapeutic option to treat type 2 diabetes. Many researches have turned their attention to the kidney as a target because renal glucose reabsorption is increased in type 2 DM. SGLT2 is a protein transporter that mediates glucose reabsorption from glomerular filtrates. In an insulin-independent manner, inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels. To date, there are a few SGLT2 inhibiting agents being clinically studied both as a monotherapy and in combination with other antidiabetic agents. This review will focus on the efficacy of SGLT2 inhibitors based on clinical studies.

Key Words: Hypoglycemic agents, Sodium glucose cotransporter 2, Type 2 diabetes mellitus